###### Strengths and limitations of this study

-   No former studies examined the impact of acute kidney injury (AKI) (and stages) on 1-year mortality after colorectal cancer surgery.

-   We used Danish population-based administrative medical and clinical quality databases.

-   Participants had uniform access to healthcare and virtually complete follow-up.

-   We defined AKI according to current guidelines Kidney Disease Improving Global Outcomes.

-   Urine output was unavailable which may have led to a minor underestimation of AKI.

Introduction {#s1}
============

Colorectal cancer (CRC) is the third most common cancer in the world with an annual incidence of 1 in 360 000.[@R1] Surgery plays a crucial role in the treatment of CRC. As the median age is above 70 years at the time of CRC diagnosis, CRC surgery is often performed in elderly patients with comorbidities. Thirty-day mortality[@R2] after CRC surgery has been reported to range from 0.4% to 23% and 7% to 65% of CRC surgery patients experience postoperative complications[@R2] within 30 days after the surgery. The wide range of complication and mortality rates could be explained by the fact that the studies are heterogeneous as regards the included procedures and the urgency of surgery.

Acute kidney injury (AKI) is a common postoperative complication[@R7] defined by a sudden decline in the excretory function of the kidneys, ranging from mild subclinical AKI to AKI patients receiving renal replacement therapy (RRT).[@R8] In a Danish population-based study of mortality after emergency surgery for colon cancer, mortality during the first 30 days after surgery was increased in patients with decreased kidney function (receiving RRT).[@R10] A small cohort study included 288 medical records from elective rectal cancer surgeries and found an AKI occurrence of 3.8% and an in-hospital mortality of 18.2% in patients with AKI, whereas, patients without AKI had an in-hospital mortality of 0.7%.[@R11] Studies of other major abdominal surgery reported postoperative AKI in 3%--35% of patients,[@R7] and found AKI to be associated with increased mortality[@R2] However, no previous study has examined the impact of AKI severity on mortality within different time frames during a year after CRC surgery. The results of the current study, therefore, intend to provide results for designing future well-targeted interventions aiming at reducing postoperative AKI and the associated mortality. Knowledge about occurrence and prognosis of postoperative AKI in patients undergoing CRC surgery could help determine whether these are high-risk patients requiring special attention after surgery. Therefore, we examined the occurrence of AKI and its prognostic impact on mortality within 1 year after CRC surgery.

Materials and methods {#s2}
=====================

Study design and setting {#s2a}
------------------------

This cohort study was conducted in Northern Denmark (the North and Central Denmark Regions, with 2 074 956 cumulative inhabitants during the study period) using prospectively collected data from medical databases.[@R12] Tax-supported healthcare is provided by the Danish National Health Service to all Danish residents. Since 1968, all residents have been assigned a unique 10-digit civil registration number (CPR number in Danish), which allows unambiguous individual-level linkage between public databases.[@R14] In the current study, CRC surgeries were performed at nine hospitals in the study area.

Patient and public involvement {#s2b}
------------------------------

Patients and public were not involved in the development or the design of this study.

Study population {#s2c}
----------------

This study included all patients who underwent first time CRC surgery during January 2005 to December 2011. Patients were identified in the Danish Colorectal Cancer Group (DCCG.dk) database.[@R16] This database, established in May 2001, contains information on patients with CRC covering demographics, treatments, complications including occurrence of patients with AKI receiving RRT and mortality within 30 days after surgery. To ensure availability of baseline laboratory data, we required residency in the study area in a period with laboratory data available.[@R12] Moreover, patients with chronic dialysis within 30 days before surgery and patients who died within 7 days after surgery were excluded from the study.

Acute kidney injury {#s2d}
-------------------

Data on plasma creatinine (PCr) (equivalent to serum creatinine \[SCr\]) were retrieved from the clinical laboratory information system (LABKA) research database.[@R12] This database contains PCr test results collected by general practices and hospitals in the study area since 1990. We defined AKI as a 50% increase in PCr, initiation of RRT within 7 days after surgery or an absolute increase in creatinine of 26 µmol/L within 48 hours. We also identified the highest AKI stage occurring within 7 days after CRC surgery according to the SCr criteria in the recent Kidney Disease Improving Global Outcomes (KDIGO) consensus criteria, as follows: no AKI, stage 1 AKI, stage 2 AKI and stage 3 AKI ([figure 1](#F1){ref-type="fig"}).[@R8] Further, we calculated mean durations of AKI (in days) defined as the number of days with AKI without a normal creatinine and with the requirement of no more than one 1 day between creatinine samples. In our main analysis, we included patients without a PCr measurement within 7 days following surgery (ie, lacking exposure information) in the group of patients without AKI, based on two rationales. First, a blood draw is minimally invasive and low cost; hence, the indication threshold is low. Second, the hospitals that contributed the most patients without exposure information followed a fast-track protocol.[@R2] This protocol advises physicians and nurses to refrain from postoperative blood analyses if a patient is healthy and recovering well. Hence, we expected patients without exposure information to resemble healthy patients without AKI. To examine this assumption, we created a second version of [table 1](#T1){ref-type="table"}, putting patients with missing AKI data in a separate category. Patients lacking one or more PCr measurements within 7 days following surgery (10.9%, n=602) appeared healthier than patients with AKI and, in general, resembled patients without AKI.

###### 

Patient characteristics by AKI stage, Denmark, 2005--2011

  Patient characteristics       Without AKI   AKI           AKI stage    All patients                
  ----------------------------- ------------- ------------- ------------ -------------- ------------ -------------
  Total (row %)                 5243 (79.7)   1337 (20.3)   858 (13.0)   284 (4.3)      195 (3.0)    6580 (100)
  Mean duration of AKI (days)   --            2.1           1.4          2.5            4.3          --
  Sex                                                                                                
   Female                       2565 (48.9)   513 (38.4)    329 (38.3)   111 (39.1)     73 (37.4)    3078 (46.8)
   Male                         2678 (51.1)   824 (61.6)    529 (61.7)   173 (60.9)     122 (62.6)   3502 (53.2)
  Age (years)                                                                                        
   0--49                        277 (5.3)     40 (3.0)      21 (2.4)     8 (2.8)        11 (5.6)     317 (4.8)
   50--59                       753 (14.4)    130 (9.7)     82 (9.6)     35 (12.3)      13 (6.7)     883 (13.4)
   60--69                       1555 (29.7)   323 (24.2)    196 (22.8)   74 (26.1)      53 (27.2)    1878 (28.5)
   70--79                       1643 (31.3)   497 (37.2)    313 (36.5)   103 (36.3)     81 (41.5)    2140 (32.5)
   ≥80                          1015 (19.4)   347 (26.0)    246 (28.7)   64 (22.5)      37 (19.0)    1362 (20.7)
  BMI                                                                                                
   Normal                       1755 (33.5)   375 (28.0)    245 (28.6)   83 (29.2)      47 (24.1)    2130 (32.4)
   Underweight                  124 (2.4)     26 (1.9)      22 (2.6)     3 (1.1)        1 (0.5)      150 (2.3)
   Overweight                   1835 (35.0)   512 (38.3)    317 (36.9)   111 (39.1)     84 (43.1)    2347 (35.7)
   Missing                      1529 (29.2)   424 (31.7)    274 (31.9)   87 (30.6)      63 (32.3)    1953 (29.7)
  Heart disease                 67 (1.3)      23 (1.7)      16 (1.9)     5 (1.8)        2 (1.0)      90 (1.4)
   Diabetes mellitus            479 (9.1)     185 (13.8)    115 (13.4)   43 (15.1)      27 (13.8)    664 (10.1)
   Liver disease                50 (1.0)      19 (1.4)      10 (1.2)     6 (2.1)        3 (1.5)      69 (1.0)
   Arterial hypertension        1260 (24)     479 (35.8)    304 (35.4)   95 (33.5)      80 (41.0)    1739 (26.4)
   OPD                          512 (9.8)     166 (12.4)    110 (12.8)   32 (11.3)      24 (12.3)    678 (10.3)
  CKD                                                                                                
   Stage 3                      834 (15.9)    347 (26.0)    251 (29.3)   59 (20.8)      37 (19.0)    1181 (17.9)
   Stage 4 or higher            39 (0.7)      48 (3.6)      25 (2.9)     2 (0.7)        21 (10.8)    87 (1.3)
  Cancer type                                                                                        
   Colon                        3481 (66.4)   862 (64.5)    540 (62.9)   186 (65.5)     136 (69.7)   4343 (66.0)
   Rectum                       1762 (33.6)   475 (35.5)    318 (37.1)   98 (34.5)      59 (30.3)    2237 (34.0)
  Urgency of surgery                                                                                 
   Elective                     4540 (86.6)   1102 (82.4)   713 (83.1)   232 (81.7)     157 (80.5)   5642 (85.7)
   Acute                        542 (10.3)    208 (15.6)    129 (15.0)   47 (16.5)      32 (16.4)    750 (11.4)
   Missing                      161 (3.1)     27 (2.0)      16 (1.9)     5 (1.8)        6 (3.1)      188 (2.9)
  UICC stage                                                                                         
   Stage I                      773 (14.7)    181 (13.5)    116 (13.5)   38 (13.4)      27 (13.8)    954 (14.5)
   Stage II                     1899 (36.2)   515 (38.5)    329 (38.3)   99 (34.9)      87 (44.6)    2414 (36.7)
   Stage III                    1412 (26.9)   387 (28.9)    247 (28.8)   97 (34.2)      43 (22.1)    1799 (27.3)
   Stage IV                     904 (17.2)    217 (16.2)    140 (16.3)   44 (15.5)      33 (16.9)    1121 (17)
   Missing                      255 (4.9)     37 (2.8)      26 (3)       6 (2.1)        5 (2.6)      292 (4.4)
  Mechanical ventilation\*      35 (0.7)      155 (11.6)    53 (6.2)     39 (13.7)      63 (32.3)    190 (2.9)
  Vasopressor/inotropes\*       54 (1.0)      163 (12.2)    56 (6.5)     38 (13.4)      69 (35.4)    217 (3.3)
  Preoperative\* radiation      564 (10.8)    142 (10.6)    94 (11)      33 (11.6)      15 (7.7)     706 (10.7)
  Preoperative† chemo           3 (0.1)       1 (0.1)       1 (0.1)      0 (0)          0 (0)        4 (0.1)
  Preadmission‡ NSAID use       532 (10.1)    150 (11.2)    93 (10.8)    36 (12.7)      21 (10.8)    682 (10.4)
  Preadmission‡ ACE use         738 (14.1)    266 (19.8)    156 (18.2)   61 (21.5)      49 (25.1)    1004 (15.3)

\*Treatment received during the CRC surgery admission.

†Defined as radiation/chemotherapy within 3 months before surgery.

‡Defined as one or more redeemed prescriptions within 90 days before the surgery.

AKI, acute kidney injury; ASA, American Society of Anesthesiologists; BMI, body mass index; CRC, colorectal cancer; CKD, chronic kidney disease; NSAID, non-steroidal anti-inflammatory drugs; OPD, obstructive pulmonary disease; UICC, Union for International Cancer Control.

![Flow chart and AKI definition. AKI, acute kidney injury; CRC, colorectal cancer; PCr, plasma creatinine.](bmjopen-2018-024817f01){#F1}

Mortality {#s2e}
---------

We obtained data on mortality, from day 8 after CRC surgery and until 1 year after this surgery, from the Danish Civil Registration System (CRS). The CRS has maintained complete information on all changes in vital status and migration for the entire Danish population since 1968.[@R14]

Covariates {#s2f}
----------

Preoperative covariates were chosen based on their potential association with AKI and with postoperative mortality.[@R7] The Danish National Patient Registry (DNPR) contains information on all hospitalisations since 1977, outpatient visits since 1994 and emergency room visits since 1995. The DNPR includes information on diagnoses, procedures and admission/discharge dates. Chronic kidney disease (CKD), a strong predictor for AKI, was identified using PCr measurements from the LABKA database. We defined CKD as an estimated glomerular filtration rate \<60 mL/min/1.73 m^2^ lasting at least 3 months within the 2 years before CRC surgery.[@R19]

The following covariates were identified from the DNPR, based on an inpatient or outpatient hospital contact for a given condition within 10 years before CRC surgery: obstructive pulmonary disease, arterial hypertension, diabetes mellitus, heart disease and liver disease. To improve the sensitivity of diabetes mellitus and obstructive pulmonary disease diagnoses, we searched the National Health Service Prescription Database (NHSPD) for previous prescriptions of medications used to treat these conditions.[@R15] The NHSPD contains records for all reimbursable drugs dispensed in community pharmacies in Denmark since 2004. Body mass index (BMI) was computed from weight and height data retrieved from the DCCG database,[@R12] divided into three categories: underweight (\<18.5 kg/m^2^), normal weight (18.5--24.9 kg/m^2^) and overweight (≥25 kg/m^2^).[@R20]

Statistical methods {#s2g}
-------------------

Patient characteristics, including demographics, comorbidities and information from the hospitalisation that included CRC surgery, were tabulated by AKI stage ([table 1](#T1){ref-type="table"}).

Because we assessed AKI within the first 7 days after surgery, we followed patients from day 8 after surgery until death, emigration or up to 1 year after surgery, whichever came first. The Kaplan-Meier method was used to compute cumulative mortality curves (1---survival function) for patients with and without AKI.[@R21] AKI was further disaggregated into AKI stages 1--3.[@R8] We computed HRs of death within 8--30, 31--90 and 91--365 days after surgery, comparing patients with AKI (and for each stage of AKI) with patients without AKI, using a Cox proportional hazards regression model adjusted for potential confounders. Confounders included age group (0--49, 50--59, 60--69, 70--79, ≥80), gender, BMI category, CKD (without CKD, stage 3 or stage 4 and higher), diabetes, obstructive pulmonary disease, hypertension, liver disease, heart disease, tumour site (colon or rectum) and urgency of surgery (acute or elective). The assumption of proportional hazards was checked graphically and found appropriate within each of the follow-up periods 8--30, 31--90 and 91--365 days after surgery. To address potential different effects in subgroups (effect modification), we repeated the analyses stratified by sex, age, CKD stage, acute versus elective surgery, surgical approach (open or minimally invasive), type of surgical procedure, diabetes mellitus and year of surgery. Moreover, a sensitivity analysis including follow-up from 0 to 30 days after surgery was performed.

### Missing data {#s2g1}

Information on lifestyle variables (BMI, smoking and alcohol use) was missing for approximately 30% of patients ([table 1](#T1){ref-type="table"}) and 20% for CKD. We did not have exact date of anastomosis leakage and other surgical complications occurring within 30 days after surgery and were therefore not able to assess the temporal relationship.

We used two approaches to address potential misclassification stemming from missing data. First, we conducted a complete-case analysis. Second, in a sensitivity analysis, we performed multiple imputations, calculating average HRs for 30 imputed datasets. In the sensitivity analysis, we estimated values for missing data for five categorical variables (CKD, urgency of surgery, BMI, smoking and alcohol intake) using all covariates, the outcome and the Nelson-Aalen estimator of the cumulative baseline hazard to observed survival time.[@R22] We expected that data were missing at random, but not completely at random, in our study because younger and healthier patients were more likely to have missing data.

### Timing of AKI {#s2g2}

We addressed timing of AKI and other complications as follows. For all patients who developed AKI within 7 days after CRC surgery, we cross-tabulated the first day of AKI with typical late complications (occurring 6--8 days postsurgery), for example, anastomosis leakage and fascial dehiscence ([figure 2](#F2){ref-type="fig"}).

![Number of patients who developed acute kidney injury, by day after surgery for all patients. No late complications=fascial dehiscence, ileus, anastomotic leakage. AKI, acute kidney injury.](bmjopen-2018-024817f02){#F2}

All analyses were conducted using the Stata software package, V.13.1 (StataCorp). All data were obtained from Danish registries and, in accordance with Danish law, their use did not require ethical approval or informed consent.

Results {#s3}
=======

Study population and AKI occurrence {#s3a}
-----------------------------------

We identified 6768 patients with CRC residing in Northern Denmark who underwent CRC surgery during 1 January 2005 to 31 December 2011. Of these, 188 patients were excluded due to either chronic dialysis (n=13) and death before start of follow-up (8 days after surgery) (n=175). Of the 175 patients dying within 7 days after surgery, 113 (64.6%) had AKI and 62 (35.4%) did not have AKI. In total, 6580 patients were included in the analyses. Postoperative AKI within 7 days after surgery occurred in 1337 patients (20.3%). AKI stage was distributed as follows among study patients: 858 had stage 1 AKI (13.0%), 284 had stage 2 AKI (4.3%) and 195 had stage 3 AKI (3.0%) ([figure 1](#F1){ref-type="fig"}). Among patients with stage 3 AKI, 67 (34.4%) received RRT. Moreover, AKI duration seemed to be more likely to be longer in patients with increasing severity of AKI.

Descriptive data {#s3b}
----------------

Total follow-up time was 5741 person-years and there was no lost to follow-up. Median age was 71.3 years, 2 678 (53.3%) patients were male and 3481 (66.0%) had colon cancer ([table 1](#T1){ref-type="table"}).

Compared with patients without AKI, those with AKI were more commonly men, aged 70 years or more, with a history of smoking and a BMI categorised as overweight ([table 1](#T1){ref-type="table"}). Patients with AKI also had a higher American Society of Anesthesiologists' Classification of Physical Health score.[@R23] Thus, patients with AKI more often had preoperative CKD, diabetes mellitus, arterial hypertension or were treated with ACE-inhibitors than patients without AKI. Moreover, postoperatively, patients with AKI more often received mechanical ventilation were treated with vasopressors/inotropes, or developed postoperative bleeding, ileus, fascial dehiscence and infectious complications than patients without AKI. The prevalence rate ratio of anastomosis leakage in patients with AKI compared with patients without AKI was 3.71 (95% CI 3.03 to 4.53) (online [supplementary table S1](#SP1){ref-type="supplementary-material"}).
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Mortality {#s3c}
---------

Cumulative 8--30 days mortality was higher in patients with AKI (10.1%) than in patients without AKI ([table 2](#T2){ref-type="table"}). Compared with patients without AKI, the adjusted HR (aHR) for patients with AKI was 4.01 (95% CI 3.11 to 5.17). Mortality increased by AKI stage and was higher for patients with stage 1 AKI than for patients without AKI ([table 2](#T2){ref-type="table"} and [figure 3](#F3){ref-type="fig"}).

###### 

Mortality outcomes (8--30, 31--90 and 91--365 days mortality) by AKI

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Mortality outcomes                                           Person-time\   No of outcomes   Cumulative mortality\   Crude HR\              Adjusted HR\*\
                                                               (days)                          % (95% CI)              (95% CI)               (95% CI)
  ------------------------------------------------------------ -------------- ---------------- ----------------------- ---------------------- ----------------------
  8--30 days mortality in patients surviving to day 7                                                                                         

  Without AKI                                                  124 430        115              2.2 (1.8 to 2.6)        Ref.                   Ref.

  With AKI                                                     30 004         135              10.1 (8.6 to 11.9)      4.83 (3.76 to 6.19)    4.01 (3.11 to 5.17)

   Stage 1                                                     19 712         62               7.2 (5.7 to 9.2)        3.38 (2.49 to 4.61)    2.62 (1.91 to 3.59)

   Stage 2                                                     6 243          30               10.6 (7.5 to 14.8)      5.16 (3.45 to 7.70)    4.83 (3.21 to 7.25)

   Stage 3                                                     4 049          43               22.1 (16.9 to 28.6)     11.20 (7.92 to 16.0)   10.40 (7.17 to 15.0)

  31--90 days mortality in patients surviving to day 30                                                                                       

  Without AKI                                                  307 089        168              3.3 (2.8 to 3.8)        Ref.                   Ref.

  With AKI                                                     70 051         92               7.8 (6.4 to 9.5)        2.45 (1.90 to 3.15)    2.08 (1.60 to2.69)

   Stage 1                                                     46 696         57               7.2 (5.6 to 9.2)        2.23 (1.65 to 3.00)    1.87 (1.38 to 2.54)

   Stage 2                                                     14 980         16               6.3 (3.9 to 10.1)       1.95 (1.17 to 3.25)    1.80 (1.08 to 3.02)

   Stage 3                                                     8375           21               13.8 (9.2 to 20.4)      4.55 (2.89 to 7.17)    3.78 (2.36 to 6.06)

  91-day to 1-year mortality in patients surviving to day 90                                                                                  

  Without AKI                                                  1 296 433      487              9.8 (9.0 to 10.7)       Ref.                   Ref.

  With AKI                                                     285 258        131              12.0 (10.3 to 14.2)     1.25 (1.03 to 1.51)    1.11 (0.92 to 1.35)

   Stage 1                                                     189 637        92               12.5 (10.3 to 15.1)     1.29 (1.03 to 1.61)    1.12 (0.89 to1.41)

   Stage 2                                                     61 774         25               10.5 (7.2 to 15.2)      1.08 (0.72 to 1.61)    1.06 (0.71 to1.58)

   Stage 3                                                     33 847         17               13.0 (8.3 to 20.0)      1.33 (0.82 to 2.16)    1.16 (0.71 to1.91)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Adjusted for age (categories: 0--49, 50--59, 60--69, 70--79 and ≥80 years), gender, BMI category, CKD stages (3--5), diabetes mellitus (yes/no), obstructive pulmonary disease, hypertension, liver disease, heart disease, tumour site and acute versus elective surgery.

AKI, acute kidney injury; BMI, body mass index; CKD, chronic kidney disease.

![Cumulative 1-year mortality by acute kidney injury stage within 7 days after colorectal cancer surgery, Northern Denmark, January 2005--December 2011. AKI, acute kidney injury; CRC, colorectal cancer.](bmjopen-2018-024817f03){#F3}

For patients who survived the first 30 days after CRC surgery, cumulative mortality during the following 31--90 days was higher in patients with AKI (7.8%) than in patients without AKI (3.3%) ([table 2](#T2){ref-type="table"}). The aHR for mortality was 2.08 (95% CI 1.60 to 2.69) in patients with AKI compared with patients without AKI. Mortality also appeared to increase by AKI stage ([table 2](#T2){ref-type="table"} and [figure 3](#F3){ref-type="fig"}).

Cumulative 91--365 days mortality following surgery initially appeared higher in patients with AKI compared with patients without AKI: 12.0% vs 9.8% ([table 2](#T2){ref-type="table"} and [figure 3](#F3){ref-type="fig"}). However, the association attenuated after adjustment (aHR=1.11, 95% CI 0.92 to 1.35).

Sensitivity analyses {#s3d}
--------------------

Sensitivity analyses performed to address missing data, including both multiple imputation and a complete-case analysis, yielded no discernible change in mortality (online [supplementary tables S2 and S3](#SP2 SP3){ref-type="supplementary-material"}). A sensitivity analysis including follow-up from 0 to 30 days after surgery was performed and showed no noticeable differences in estimates as compared with follow-up from day 8 (online [supplementary table S4](#SP4){ref-type="supplementary-material"}).
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Subgroup analyses {#s3e}
-----------------

While we observed no major differences between subgroups, our analyses yielded aHRs with very wide CIs, making the point estimates less reliable and precluding conclusions about the presence of effect modification (online [supplementary figure S1](#SP5){ref-type="supplementary-material"}).

10.1136/bmjopen-2018-024817.supp5

Timing of AKI and late complications after surgery {#s3f}
--------------------------------------------------

Overall, as well as in patients with late complications such as anastomosis leakage or fascial dehiscence, AKI occurred most frequently within 1--4 days after surgery.

Discussion {#s4}
==========

Key results {#s4a}
-----------

In this population-based cohort study, we found that 20% of patients developed AKI within 7 days following CRC surgery. AKI was associated with a twofold to threefold higher risk of mortality within the first 90 days after CRC surgery even in patients with stage 1 AKI. In the period 91--365 days after surgery, mortality was similar in patients with and without AKI, after adjustment. During the first 8--30 days after surgery, the association between postoperative AKI and mortality appeared to increase with higher AKI stage. In general, patients with AKI had more postoperative complications.

Previous studies {#s4b}
----------------

Two studies reported on kidney dysfunction and mortality in postoperative patients with CRC.[@R10] Iversen *et al* examined postoperative complications and mortality in 2157 Danish patients with CRC who underwent emergency surgery.[@R10] However, their study included only patients with AKI receiving RRT. While AKI was reported by surgeons to the DCCG database within 30 days, the severity of AKI in patients receiving RRT reduced the risk of under-reporting. Iversen *et al* found that 2.0% of postoperative patients with CRC had AKI and were receiving RRT and 30-day mortality among these patients was 68%. This is comparable with our results for patients with stage 3 AKI who received RRT.[@R10] The other study did investigate occurrence of all AKI stages after rectal cancer resections, although mortality (in-hospital) was only reported for overall AKI (18.2%).[@R11]

Our results also are consistent with reported prevalences of 3%--35% for postoperative AKI and 0.5%--25% rates of all-cause postoperative mortality within the first year in patients who underwent major abdominal surgery.[@R7]

Strengths and limitations {#s4c}
-------------------------

The risk of selection bias in our study was limited for three reasons. First, patients were included in relevant databases as part of the prospective registration of data for administrative purposes (DNPR, CRS, LABKA and NHSPD) or to evaluate clinical quality (DCCG) in Danish hospitals. Second, study participants had uniform access to healthcare with complete follow-up. Third, the completeness of the databases (85%--99%)%) and of most variables were high.[@R12]

Supported by the results of our sensitivity analyses, we conclude that misclassification due to inclusion of patients lacking exposure information in the group without AKI (11%) posed a minor risk of information bias.

The KDIGO criteria include urine output. As in many other studies in non-intensive care unit settings, AKI staging for our study was performed without information on urine output, which was unavailable. Consequently, the lack of data on urine output may have led to misclassification that could have biased our results towards the null. We expect that the bias is limited since SCr alone has a stronger association with mortality than urine output.[@R23]

In our study, AKI may have been related to other surgical complications and accompanying reoperations. Unfortunately, the date of postoperative complications is unavailable in the DCCG database. Therefore, we could not assess the timing of AKI and development of other postoperative complications that could potentially lead to AKI. Also, our study was limited by the lack of information on type of anaesthesia, perioperative fluid administration and contrast exposure.

As well, information on BMI (self-reported at hospital admission) was missing for 30% of patients. A multiple imputation analysis addressing this missing information yielded only minor changes in our results. Despite this analysis and extensive adjustment for potential confounders including lifestyle variables, we cannot entirely rule out unmeasured confounding from such factors as fluid management, for which we had no information, and residual confounding. Still, our study clearly showed that AKI is a marker for increased risk of death after CRC surgery.

Interpretation {#s4d}
--------------

AKI is a multifactorial condition, and in the operative setting, relevant factors include response to anaesthesia (eg, peripheral vasodilatation and myocardial depression) and surgery (increase in the antidiuretic hormone and aldosterone), as well as the effect of fluid depletion. Major surgery introduces the risk of fluid depletion at several stages, for example, preoperative nil-by-mouth regimen, perioperative blood and intravascular fluid loss, extravasation of fluid from the vascular compartment (third-space effect), insensible fluid losses and the pathology of the disease itself.

AKI also could develop from complications such as sepsis or electrolyte derangement associated with ileus. This could be due to global hypoperfusion of the kidney if the afferent arteriole dilation and efferent arteriole vasoconstriction response initiated by the kidney does not result in adequate glomerular filtration. Further, hypotension can lead to dysfunctional intrarenal microcirculation due to patchy areas of hypoperfusion in the kidney and potentially add to the risk of developing AKI.[@R25]

AKI most frequently occurred during the initial days following surgery. In patients with late complications (ileus, fascial dehiscence or anastomotic leakage), there was an additional peak after 5--6 days, corresponding to reoperations for these complications. AKI might also contribute to the development of such postoperative complications. This hypothesis needs to be investigated further in studies in which the timing of AKI and postoperative complications can be ascertained.

The results of the study are generalisable to other CRC surgery settings with a population resembling the Danish population despite our restriction to North Denmark Region and Central Denmark Region, because the Danish Healthcare system is homogeneous across regions, hospitals, coding practice, socioeconomic characteristics and healthcare usage.[@R29]

In conclusion, AKI occurred in approximately 20% of patients undergoing CRC surgery and was associated with increased mortality throughout the first 90 days following surgery, even in patients with stage 1 AKI (ie, with more than a 50% increase in creatinine). Thus, patients with even small increases in creatinine may require enhanced attention to achieve early detection of AKI and correction of fluid and electrolyte derangement. An interventional study is required to examine whether such interventions will reduce the rate or at least the severity of postoperative complications.
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